Robotaxi, Optimus, and Terafab compound on a cash engine that never slowed.

This is an update of my original Tesla deep dive and Q4 2025 ER digest.

Share

Manufacturing efficiency has compounded hard since 2022. The chart below shows OCF ÷ CapEx. It’s cyclical because Tesla periodically cuts prices to drive volume, but the peaks are what matter. Those peaks have held in the 2.5–2.8x range even with rates ~4 to 5% higher than the 2022 era. Normalise for that rate drag and the post 2022 cash generation never actually slowed. It accelerated in relative terms.

Q1 2026 confirms the inflection: EMEA deliveries +150% QoQ, Berlin at a record 61k units, auto margin ex credits sequentially from 17.9% to 19.2%, highest Q1 backlog in two years. CFO Vaibhav Taneja shared how this was primarily driven by Tesla delivering more value per dollar to end customers:

Whilst the recent increase in gas prices has had a positive impact on the order rate, this improvement started before the uptrend in gas prices.

This is due to the work done by the Tesla team in bringing more compelling and affordable vehicles to market. 10 years back, when we launched Model 3 in the U.S. with a promise of $35,000 starting price, which if you adjust today for inflation translates to about $48,000 in today’s dollar terms.

The starting price of Model 3 today is way less than that while the product is way more compelling from where it started.

Tesla is a machine that prints autos, batteries, and soon robots. Manufacturing efficiency is the precursor of a value:price ratio no one can match at scale, which drives cash production. The $25B+ 2026 CapEx ramp will pull free cash flow negative for the year, but will also add new levers to monetise the underlying efficiency gains: Robotaxi at scale, Optimus production, and vertical integration into silicon via Terafab. Each of these will emerge as a multiplier of cash from operations, which in a CapEx cycle is a good proxy for free cash flow.

LTM operating cash flow has gone from $9B to $16B in five years, through the rate hiking cycle and through Tesla’s most aggressive price cuts. That is the baseline the new levers compound on.

Quick math on one of those levers. Robotaxi at 1M autonomous vehicles, 30k miles per vehicle per year, $0.40 contribution margin per mile is $12B in annual high margin recurring revenue, that’s highly accretive to the cash flow profile. Dropped on top of a $16B base that is still growing. And that is one lever of three. Optimus and Terafab sit behind it. This is what makes the next 2 to 5 years asymmetric. The cash engine that funds the CapEx is bigger than it has ever been and still scaling.

Further, cash from operations and CapEx pointing in opposite directions in Q1 2026 suggest the revenue may be even more accretive than expected. Both going up at the same time. Tesla is investing more aggressively than ever and still generating more cash than ever. The 2026 ramp accelerates the CapEx line further. The OCF line keeps compounding behind it, on a base that is structurally more efficient than the last cycle.

⚡ If you enjoyed the post, please feel free to share with friends, drop a like and leave me a comment.

You can also reach me at:

Twitter: @alc2022

LinkedIn: antoniolinaresc

These are opinions only of the individual author. The contents of this piece do not contain investment and/or medical advice and the information provided is for educational purposes only and no discussions constitute an offer to sell or the solicitation of an offer to buy any securities of any company or any drug or medical treatment. All content is purely subjective and you should do your own due diligence.

Antonio Linares makes no representation, warranty or undertaking, express or implied, as to the accuracy, reliability, completeness or reasonableness of the information contained in the piece. Any assumptions, opinions and estimates expressed in the piece constitute judgments of the author as of the date thereof and are subject to change without notice. Any projections contained in the Information are based on a number of assumptions as to market conditions and there can be no guarantee that any projected outcomes will be achieved. Antonio Linares does not accept any liability for any direct, consequential or other loss arising from reliance on the contents of this presentation. Antonio Linares is not acting as your financial, legal, accounting, tax, medical or other adviser or in any fiduciary capacity.